Saturday, February 14, 2026 2/14/2026

SCREENING FOR INHIBITORS OF TLR8 FOR TREATMENT OF RHEUMATOID ARTHRITIS

Award Number: R43AI100376
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2012
PERIOD OF PERFORMANCE END DATE: 05/31/2015

Group Awards By:

View Award Description

SCREENING FOR INHIBITORS OF TLR8 FOR TREATMENT OF RHEUMATOID ARTHRITIS - DESCRIPTION (provided by applicant): Autoimmune diseases develop when the adaptive immune response targets self-antigens, leading to inflammation and tissue destruction. The innate immune system faces the same fundamental challenge as the adaptive immune system - distinguishing self from non-self antigens - and there is now considerable evidence that recognition of self nucleic acids through toll-like receptors (TLRs) can contribute significantly t sterile inflammation and autoimmunity, with the clearest example being the role played by TLR9 and TLR7 in the pathogenesis of systemic lupus erythematosus (SLE). One of the innate receptors for RNA, TLR8, is a potent stimulator of inflammatory cytokines such as IL6 and TNF-¿, and its expression by multiple cell types involved in inflammatory diseases suggests likely involvement in autoimmunity. However, the lack of useful animal models, a consequence of the very different ligand specificity of human TLR8 and its rodent orthologs, has proven to be a major limitation in the study of TLR8 function. We have developed new tools that we hope will help better understand the biology of TLR8 and that have provided important new evidence for a role of TLR8 signaling in rheumatoid arthritis. The key objective of this proposal is to develop small-molecule antagonists of human TLR8 that can be tested for efficacy, first in the novel animal models we have developed, and ultimately in patients. The principal activities will include: "Establishment of a cell-based screening strategy for huTLR8 antagonists. "Screening multiple libraries of well-characterized compounds. "Confirmation of the specificity of hits from these screening activities. If successful, this project will demonstrate the feasibility of developng a small-molecule inhibitor for human TLR8, and will provide the lead compounds that can be rigorously tested for potential use in the treatment of rheumatoid arthritis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $105,088 )
2013	2013	DYNAVAX TECHNOLOGIES CORPORATION	2929 7th St Ste 100	Berkeley	CA	94710	ALAMEDA	USA	Allergy and Infectious Diseases Research	000	2	6/7/2013	NON-COMPETING CONTINUATION	$105,088
														Subtotal = $105,088

Issue Date FY: 2012 ( Subtotal = $299,830 )
2012	2012	DYNAVAX TECHNOLOGIES CORPORATION	2929 7th St Ste 100	Berkeley	CA	94710	ALAMEDA	USA	Allergy and Infectious Diseases Research	000	1	5/29/2012	NEW	$299,830
														Subtotal = $299,830

Grand Total All Awards = $404,918

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SCREENING FOR INHIBITORS OF TLR8 FOR TREATMENT OF RHEUMATOID ARTHRITIS

Award Number: R43AI100376

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2012

PERIOD OF PERFORMANCE END DATE: 05/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer